Paper - WANFANG MED ONLINE

You Position: Home > Paper

HBV infection and kidney injury

( views:279, downloads:317 )

Author:: No author available

Journal Title:: 中华临床感染病杂志

Issue:: 1

DOI:: 10.3760/cma.j.issn.1674-2397.2016.01.015

Key Word:: 肝炎,乙型,慢性;肾炎;肝肾综合征;抗病毒药;Hepatitis B,chronic;Nephritis;Hepatorenal syndrome;Antiviral agents

Abstract： Chronic HBV infection may not only cause liver damage , but also lead to renal injury . HBV-related kidney injuries mainly include ( 1 ) HBV-associated glomerulonephritis , ( 2 ) hepatorenal syndrome, and (3) kidney injuries caused by long-term nucleos(t)ide analogues therapy.This paper mainly reviews the pathogenesis and therapeutic principle of HBV-related kidney injuries , so as to provide the foundation for clinical management .

Reference

[1]黄燕,范学工.应用免疫抑制剂或化疗药物的慢性乙肝患者HBV再激活及其治疗[J].2012,(8).
[2]张瑜.乙肝病毒相关性肾炎肾小球足细胞病变机制的研究[D].2010.
[3]万十千,万学发,朱清静,等.高低剂量特利加压素治疗肝硬化合并1型肝肾综合征的比较研究[J].2014,(5).
[4]刘晓宇,周莉,段钟平,等.阿德福韦酯长期治疗对慢性乙型肝炎患者PBMCs中线粒体DNA的影响[J].2012,(1).
[5]卢宏柱,周建华.乙型肝炎病毒X基因对大鼠肾小球系膜细胞增殖和肿瘤坏死因子α表达的影响[J].2008,(3).
[6]卢宏柱,樊启红,周建华.乙型肝炎病毒X基因转染大鼠系膜细胞对细胞增殖及IL-1β,IL-6表达的影响[J].2009,(11).
[7]陈军宝,张洪英,雷辉,等.HBV X蛋白通过激活PI3K/Akt信号通路诱导大鼠肾系膜细胞增殖[J].2013,(8).
[8]苏婷婷,邱源旺,黄利华,等.恩替卡韦治疗乙型肝炎病毒相关性肾炎的疗效观察[J].2014,(3).
[9]卢宏柱,周建华.乙型肝炎病毒X蛋白通过激活细胞外蛋白调节激酶转导机制上调大鼠系膜细胞肿瘤坏死因子-α的表达[J].2009,(10).
[10]Cun-Liang Deng,Xin-Wen Song,Hai-Jun Liang,etc.Chronic hepatitis B serum promotes apoptotic damage in human renal tubular cells[J].2006,(11).
[11]孙莉静,于建平,袁伟杰,等.Bcl-2和Bax在乙型肝炎病毒相关性肾炎患者肾组织中的表达[J].2007,(5).
[12]尹晓玲,周建华.乙型肝炎病毒X蛋白对小鼠足细胞补体调节蛋白CD59和Crry表达的影响[J].2010,(12).
[13]于艳,张静,王汉民,等.乙型肝炎病毒相关性肾炎肾组织中HBx、MHBst mRNA的表达及其意义[J].2008,(9).
[14]苏淼,赵彩彦,张莉,等.SLC34 A1和 RGS14单核苷酸多态性与阿德福韦酯治疗的慢性乙型肝炎患者血磷浓度的相关性[J].2014,(6).
[15]庄永泽,魏丽芳,余英豪,等.乙型肝炎病毒相关性膜性肾病中nephrin的表达及意义[J].2011,(9).
[16]Imaoka T,Kusuhara H,Adachi M,etc.Functional involvement of multidrug resistance-associated protein 4 (MRP4/ABCC4) in the renal elimination of the antiviral drugs adefovir and tenofovir.[J].2007,71(2).
[17]Connolly CA,Adhikari M,Coovadia HM,etc.HLA class I and II in black children with hepatitis B virus-associated membranous nephropathy.[J].2002,61(4).
[18]Hoying Brandt A,Santoianni R,Hosseini SH,etc.Tenofovir renal toxicity targets mitochondria of renal proximal tubules.[J].2009,89(5).
[19]Mendel DB,Lin DC,Ho ES,etc.Cytotoxicity of antiviral nucleotides adefovir and cidofovir is induced by the expression of human renal organic anion transporter 1.[J].2000,11(3).
[20]Lee HS,Kang SJ,Oh KH,etc.Two subtypes of hepatitis B virus-associated glomerulonephritis are associated with different HLA-DR2 alleles in Koreans.[J].2003,62(6).
[21]Rollot, Florence,Nazal, Eve-Marie,Chauvelot-Moachon, Laurence,etc.Tenofovir-Related Fanconi Syndrome with Nephrogenic Diabetes Insipidus in a Patient with Acquired Immunodeficiency Syndrome: The Role of Lopinavir-Ritonavir-Didanosine.[J].2003,37(12).
[22]Alessandria, Carlo,Graupera, Isabel,Andrealli, Alida,etc.Terlipressin and albumin for type-1 hepatorenal syndrome associated with sepsis[J].2014,60(5).
[23]McKeage K,Keam SJ.Telbivudine: a review of its use in compensated chronic hepatitis B.[J].2010,70(14).
[24]KAR NENG LAI,FERNAND MAC-MOUNE LAI,KEENG WAI CHAN,etc.The Clinico-pathologic Features of Hepatitis B Virus-associated Glomerulonephritis[J].1987,63(1).
[25]Mindikoglu,A.L.,Weir,M.R..Current concepts in the diagnosis and classification of renal dysfunction in cirrhosis[J].2013,38(4).
[26]Benhamou, Yves,de Ledinghen, Victor,Zoulim, Fabien,etc.Prevalence of renal abnormalities in chronic HBV infection: The HARPE study[J].2015,35(1).
[27]Moszkowska G,Zurowska A,Kondeatis E,etc.HLA-DRB and -DQB1 alleles in Polish patients with hepatitis B associated membranous nephropathy.[J].1998,52(2).
[28]Wu C,Chen L,Fan X.Replication and infectivity of hepatitis B virus in HBV-related glomerulonephritis.[J].2009,13(3).
[29]Merkel C,Ring Larsen H,Gines P,etc.EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis.[J].2010,53(3).
[30]Teuber, P.,Appenrodt, B.,Regenstein, F.,etc.Impact of liver transplantation on the survival of patients treated for hepatorenal syndrome type 1[J].2011,17(11).
[31]Hu L,Sun H,Chen L,etc.Hepatitis B virus X protein enhances cisplatin-induced hepatotoxicity via a mechanism involving degradation of Mcl-1.[J].2011,85(7).
[32]Nozomu Tanji,Kurenai Tanji,Neeraja Kambham,etc.Adefovir nephrotoxicity: Possible role of mitochondrial DNA depletion[J].2001,32(7).
[33]Sydney, Tang,Fernand Mac-Moune, Lai,Yun Hoi, Lui,etc.Lamivudine in hepatitis B-associated membranous nephropathy.[J].2005,68(4).
[34]Deray AG,Villard E,Goyenvalle C,etc.Association between ABCC2 gene haplotypes and tenofovir-induced proximal tubulopathy.[J].2006,194(11).
[35]Zimmermann, Anthony E.,Pizzoferrato, Thomas,Bedford, John,etc.Tenofovir-Associated Acute and Chronic Kidney Disease: A Case of Multiple Drug Interactions.[J].2006,42(2).
[36]Frances R,Moreu R,Such J,etc.Bacterial DNA in patients with cirrhosis and noninfected ascites mimics the soluble immune response established in patients with spontaneous bacterial peritonitis[J].2008,47(3).
[37]Runyon BA.Management of adult patients with ascites due to cirrhosis: an update.[J].2009,49(6).
[38]Krag A,Bendtsen F,Henriksen JH,etc.Low cardiac output predicts development of hepatorenal syndrome and survival in patients with cirrhosis and ascites.[J].2010,59(1).
[39]Kung-Hao Liang,Yi-Cheng Chen,Chao-Wei Hsu,etc.Decrease of Serum Angiotensin Converting Enzyme Levels Upon Telbivudine Treatment for Chronic Hepatitis B Virus Infection and Negative Correlations Between the Enzyme Levels and Estimated Glumerular Filtration Rates.[J].2014,14(1).
[40]McCullough, Arthur J.,Raina, Rupesh,Garg, Gaurav,etc.Management and outcome in hepatorenal syndrome: need for renal replacement therapy in non-transplanted patients[J].2014,46(4).
[41]Hong-Yu Jia,Feng Ding,Jian-Yang Chen,etc.Early kidney injury during long-term adefovir dipivoxil therapy for chronic hepatitis B[J].2015,(12).
[42]Sugantha Govindarajan,Cynthia C. Nast,William L. Smith,etc.Immunohistochemical distribution of renal prostaglandin endoperoxide synthase and prostacyclin synthase: Diminished endoperoxide synthase in the hepatorenal syndrome[J].1987,7(4).
[43]Hassane Izzedine,Vincent Launay-Vacher,Gilbert Deray.Antiviral Drug-Induced Nephrotoxicity[J].2005,45(5).
[44]Zhou, Yi,Yuan Wei, Jie,Zhu, Nan.The efficacy of anti-viral therapy on hepatitis B virus-associated glomerulonephritis: A systematic review and meta-analysis.[J].1900,10(2).
[45]K N, Lai,F M, Lai,J S, Tam.Comparison of polyclonal and monoclonal antibodies in determination of glomerular deposits of hepatitis B virus antigens in hepatitis B virus-associated glomerulonephritides.[J].1989,92(2).
[46]W J, Brzosko,K, Krawczyński,T, Nazarewicz,etc.Glomerulonephritis associated with hepatitis-B surface antigen immune complexes in children.[J].1974,2(7879).
[47]Pritchard JB,Fuller MD,Mendel DB,etc.The antiviral nucleotide analogs cidofovir and adefovir are novel substrates for human and rat renal organic anion transporter 1.[J].1999,56(3).
[48]Burton Combes,James Shorey,Arnaldo Barrera,etc.Glomerulonephritis with Deposition of Australia Antigen-Antibody Complexes in Glomerular Basement Membrane[J].1971,298(7718).
[49]H, Hirose,K, Udo,M, Kojima,etc.Deposition of hepatitis B e antigen in membranous glomerulonephritis: identification by F(ab')2 fragments of monoclonal antibody.[J].1984,26(3).
[50]Yong-Feng Yang,Qing-Fang Xiong,Wei Zhao,etc.Complete remission of hepatitis B virus-related membranous nephropathy after entecavir monotherapy[J].2012,36(5).
[51]JakeLiang,T.,Collins,M.T.,Kleiner,D.E.,etc.Renal tubular dysfunction during long-term adefovir or tenofovir therapy in chronic hepatitis B[J].2012,35(11).
[52]Pipili,C.L.,Papatheodoridis,G.V.,Cholongitas,E.C..Treatment of hepatitis B in patients with chronic kidney disease[J].2013,84(5).
[53]Luis Ruiz-del-Arbol,Alberto Monescillo,Carlos Arocena,etc.Circulatory function and hepatorenal syndrome in cirrhosis[J].2005,42(2).
[54]Ming-Hung Tsai,Yun-Shing Peng,Yung-Chang Chen,etc.Adrenal insufficiency in patients with cirrhosis, severe sepsis and septic shock[J].2006,43(4).
[55]Santoianni R,Hosseini SH,Lewis W,etc.Tenofovir renal proximal tubular toxicity is regulated by OAT1 and MRP4 transporters.[J].2011,91(6).
[56]Mónica Guevara,Pere Ginès,Juan Carlos Bandi,etc.Transjugular intrahepatic portosystemic shunt in hepatorenal syndrome: Effects on renal function and vasoactive systems[J].1998,28(2).
[57]Gadi Lalazar,Deborah Rund,Daniel Shouval.Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies[J].2007,136(5).
[58]Beck,L.,Bomback,A.S.,Choi,M.J.,etc.KDOQI US commentary on the 2012 KDIGO clinical practice guideline for glomerulonephritis[J].2013,62(3).
[59]Debernardi-Venon W,Morgando A,Alessandria C,etc.Noradrenalin vs terlipressin in patients with hepatorenal syndrome: A prospective, randomized, unblinded, pilot study.[J].2007,47(4).
[60]Liu,Y.,Zhao,P.,Qu,Z.,etc.Frequency of CD4+CXCR5+ TFH cells in patients with hepatitis b virus-associated membranous nephropathy[J].2014,22(1).
[61]Lee,C.-M.,Lu,S.-N.,Tseng,P.-L.,etc.A comparison of efficacy and safety of 2-year telbivudine and entecavir treatment in patients with chronic hepatitis B: A match-control study[J].2014,20(2).
[62]H. L.Y. Chan,Y. C. Chen,E. J. Gane,etc.Randomized clinical trial: efficacy and safety of telbivudine and lamivudine in treatment-naïve patients with HBV-related decompensated cirrhosis[J].2012,19(10).